Last reviewed · How we verify
A Multicentre, Double-blind, Active Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Controlled Release Paroxetine in the Treatment of Major Depression
The study is to investigate the non-inferior efficacy of Paroxetine Controlled Release to Paroxetine Immediate Release, as well as the drug tolerability profile when treated on patients with Major Depression.
Details
| Lead sponsor | GlaxoSmithKline |
|---|---|
| Phase | Phase 3 |
| Status | COMPLETED |
| Enrolment | 362 |
| Start date | 2006-12 |
Conditions
- Depressive Disorder, Major
- Major Depressive Disorder (MDD)
Interventions
- Paroxetine CR
- Paroxetine IR
Primary outcomes
- Scores on depression rating scale at treatment week 1,2,3,4,6 and 8.
Countries
China